Author:
Lee Jean W.,Weiner Russ S.,Sailstad Jeff M.,Bowsher Ronald R.,Knuth Dean W.,O’Brien Peter J.,Fourcroy Jean L.,Dixit Rakesh,Pandite Lini,Pietrusko Robert G.,Soares Holly D.,Quarmby Valerie,Vesterqvist Ole L.,Potter David M.,Witliff James L.,Fritche Herbert A.,O’Leary Timothy,Perlee Lorah,Kadam Sunil,Wagner John A.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology
Reference40 articles.
1. 1. J. A. DiMasi, R. W. Hansen, and H. G. Grabowski. The price of innovation: new estimates of drug development costs. J. Health Econ. 22:151–185 (2003).
2. 2. G. Levy. Mechanism-based pharmacodynamics modeling. Clin. Pharmacol. Ther. 56:356–358 (1994).
3. 3. C. C. Peck, W. H. Barr, L. Z. Benet, J. Collino, R. E. Desjardins, D. E. Furst, J. G. Harter, G. Levy, T. Ludden, and J. H. Rodman. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Pharm. Sci. 81:600–610 (1992).
4. 4. W. A. Colburn. Selecting and validating biologic markers for drug development. J. Clin. Pharmacol. 37:355–362 (1997).
5. 5. P. R. Jadhav, M. U. Mehta, and J. V. S. Gobburu. How biomarkers can improve clinical drug development. Am. Pharm. Rev. 7:62–64 (2004).
Cited by
167 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献